Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.44 |
| ▸ | TUBB | P07437 | 2/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8136809 | 0.84 | TP53 (0.52) | CRHR1TP53HSD17B10KDM4ESRD5A1 | |
| SCHEMBL2192949 | 0.82 | KDM4E (0.72) | CRHR1HSD17B10HTR3EHTR3BHTR3A | |
| SCHEMBL11119022 | 0.82 | HTT (0.55) | TP53HSD17B10KDM4ESMN1; SMN2HTT | |
| SCHEMBL2760313 | 0.81 | HSD17B10 (0.57) | TP53HSD17B10KDM4EAKR1C3HTT | |
| SCHEMBL24685888 | 0.81 | TP53 (0.52) | TP53HSD17B10KDM4EHTTHIF1A | |
| SCHEMBL1922766 | 0.80 | TP53 (0.49) | CRHR1TP53HSD17B10KDM4EHTT | |
| SCHEMBL3866085 | 0.80 | HSD17B10 (0.59) | TP53HSD17B10KDM4EAKR1C3SMN1; SMN2 | |
| SCHEMBL30168124 | 0.80 | HSD17B10 (0.59) | TP53HSD17B10KDM4EAKR1C3SMN1; SMN2 | |
| SCHEMBL12070446 | 0.80 | HSD17B10 (0.55) | CRHR1TP53HSD17B10KDM4EAKR1C3 | |
| SCHEMBL22430527 | 0.80 | CYP11B1 (0.48) | CRHR1TP53HSD17B10KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | claimed |
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | disclosed |
| EP-1611133-B1 | CONDENSED N-HETEROCYCLIC COMPOUND AND USE THEREOFF AS CRF RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORK LTD (IE) | 2010-07-07 | — | — | EP | disclosed |
| EP-2186813-A1 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SmithKline Beecham (Cork) Limited (IE) | 2010-05-19 | — | — | EP | disclosed |
| US-7427630-B2 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMACO PUERTO RICO INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070066640-A1 | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-03-22 | — | — | US | disclosed |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | NEUROCRINE BIOSCIENCES, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1611133-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC. CSC, The United States Corporation Company (PR) | 2006-01-04 | — | — | EP | disclosed |
| EP-1583531-A1 | HETEROARYL- SUBSTITUTED PYRROLO' 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB Pharmco Puerto Rico Inc (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004094420-A1 | CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004062665-A1 | HETEROARYL- SUBSTITUTED PYRROLO` 2, 3- B! PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO PUERTO RICO INC (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | CRH, CRHR1, CRHR2 | CRHR1 2/4885TP53 4696/4885HSD17B10 2148/4885 |
| US-20070066640-A1 | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885TP53 4604/4885HSD17B10 1777/4885 |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | CRHR2, NR3C2, CRHR1 | CRHR1 3/4885TP53 4782/4885HSD17B10 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.